Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment

Submitted by Anonymous on

BackgroundSomatic EGFR mutations are prevalent in lung adenocarcinoma but are exceptionally rare in primary squamous cell carcinoma (SCC). Consequently, whil Abstract Background: Somatic EGFR mutations are prevalent in lung adenocarcinoma but are exceptionally rare in primary squamous cell carcinoma (SCC)....

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Submitted by Anonymous on

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC Non-dilutive Biomedical Catalyst funding from Innovate UK will support the advancement of Promatix's lead cis-bispecific antibody-drug conjugate (ADC), PBS293-exatecan, towards development candidate nominationAward funds...

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Submitted by Anonymous on

Für Sie zusammengefasst Innovate UK funds Promatix to advance PBS293 ADC Funding for scale up and CDX PDX IND safety studies Extending EGFR × EphA2 to oesophageal and NSCLC EQS-News: Promatix Biosciences, Ltd. / Key word(s): Miscellaneous Promatix Biosciences Awarded...

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC Promatix Biosciences, Ltd. Tue, July 28, 2026 at 3:30...

YH42946, a novel and selective tyrosine kinase inhibitor, demonstrates potent antitumor activity against EGFR exon 20 insertion mutations and HER2 alterations in NSCLC

Submitted by Anonymous on

EGFR exon 20 insertion mutations and HER2 alterations are oncogenic drivers in non–small cell lung cancer (NSCLC) with limited therapeutic options. YH42946 is an orally available tyrosine kinase inhibitor designed to selectively target these alterations while sparing EGFR wild-type. Here,...

ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

Submitted by Anonymous on

AbstractBackground Acquired resistance significantly limits the long-term clinical benefit of osimertinib in EGFR-mutant lung adenocarcinoma (LUAD). However, the early non-genetic adaptations and microenvironmental crosstalk that enable initial tumor survival remain poorly defined. This study aimed to elucidate the epigenetic-immune mechanisms...

Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlim

Submitted by Anonymous on

INDICATION and IMPORTANT SAFETY INFORMATION for VOYXACT® (sibeprenlimab-szsi) INDICATION VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria....

Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026

Submitted by Anonymous on

PRINCETON, N.J.--(BUSINESS WIRE)--Jul 27, 2026-- Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), announces that new data from the Phase 3 VISIONARY study will be presented at the GlomCon Hawaii 2026 conference taking place August 3-7, 2026. Building on recently reported...

Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026

Submitted by Anonymous on

PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), announces that new data from the Phase 3 VISIONARY study will be presented at the GlomCon Hawaii 2026 conference taking place August 3-7, 2026. Building on recently reported topline results, the...

Subscribe to Newsfeed